Cardiac Uptake of Metformin, Visualized by Positron Emission Tomography
Phase 1
Completed
- Conditions
- Heart Failure, Systolic
- Interventions
- Radiation: 11C-metformin
- Registration Number
- NCT03122769
- Lead Sponsor
- Henrik Wiggers
- Brief Summary
The purpose of the study is to evaluate if metformin is taken up into the failing myocardium. Recent experimental and epidemiological studies have shown beneficial effects of metformin on heart failure. It is unknown whether this effect is direct or indirect.
The aim of the study is to investigate if metformin is taken up in heart failure using a novel 11C-metformin tracer and positron emission tomography (PET).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
- Patients with chronic heart failure, Left Ventricular Ejection Fraction <45%
- New York Heart Association (NYHA) class I, II, III
- Relatively preserved renal function (eGFR > 30 ml/min)
- Ability to understand the written patient information and to give informed consent
- Negative p-HCG for women of childbearing potential
Exclusion Criteria
- Known allergy to metformin
- Age < 18 years
- Current abuse of alcohol or drugs
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 11C-metformin 11C-metformin All participants allocated to the study will be included in this arm
- Primary Outcome Measures
Name Time Method Metformin uptake in the failing myocardium 12 months Cardiac uptake is evaluated through analysis of acquired PET-images.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Aarhus University Hospital, Department of Cardiology, Palle Juul-Jensens Boulevard 99
🇩🇰Aarhus N, Denmark